- Home
- SYBX vs BLRX Comparison
SYBX vs BLRX Comparison
Compare SYBX & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- BLRX
- Stock Information
- Founded
- SYBX N/A
- BLRX 2003
- Country
- SYBX United States
- BLRX Israel
- Employees
- SYBX N/A
- BLRX N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- BLRX Health Care
- Exchange
- SYBX Nasdaq
- BLRX Nasdaq
- Market Cap
- SYBX 13.6M
- BLRX 15.3M
- IPO Year
- SYBX N/A
- BLRX 2011
- Fundamental
- Price
- SYBX $1.20
- BLRX $4.70
- Analyst Decision
- SYBX
- BLRX Strong Buy
- Analyst Count
- SYBX 0
- BLRX 2
- Target Price
- SYBX N/A
- BLRX $19.00
- AVG Volume (30 Days)
- SYBX 6.9K
- BLRX 77.4K
- Earning Date
- SYBX 08-07-2025
- BLRX 08-14-2025
- Dividend Yield
- SYBX N/A
- BLRX N/A
- EPS Growth
- SYBX N/A
- BLRX N/A
- EPS
- SYBX 0.21
- BLRX N/A
- Revenue
- SYBX N/A
- BLRX $22,340,000.00
- Revenue This Year
- SYBX N/A
- BLRX N/A
- Revenue Next Year
- SYBX N/A
- BLRX N/A
- P/E Ratio
- SYBX $5.92
- BLRX N/A
- Revenue Growth
- SYBX N/A
- BLRX 91.68
- 52 Week Low
- SYBX $0.90
- BLRX $2.30
- 52 Week High
- SYBX $1.88
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- SYBX 54.75
- BLRX 57.56
- Support Level
- SYBX $1.18
- BLRX $4.05
- Resistance Level
- SYBX $1.27
- BLRX $4.64
- Average True Range (ATR)
- SYBX 0.05
- BLRX 0.38
- MACD
- SYBX -0.00
- BLRX -0.01
- Stochastic Oscillator
- SYBX 58.33
- BLRX 86.17
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.